» Articles » PMID: 2195865

Studies of Left Ventricular Dysfunction (SOLVD)--rationale, Design and Methods: Two Trials That Evaluate the Effect of Enalapril in Patients with Reduced Ejection Fraction

Overview
Journal Am J Cardiol
Date 1990 Aug 1
PMID 2195865
Citations 23
Affiliations
Soon will be listed here.
Abstract

The Studies of Left Ventricular Dysfunction (SOLVD) is an extensive program of research that has 3 components. (1) Two large double-blind randomized trials evaluate the effects of enalapril on mortality, morbidity and quality of life of patients with left ventricular (LV) dysfunction with overt congestive heart failure (CHF) (Treatment Trial in 2,500 patients) and without overt CHF (Prevention Trial in 4,600 patients). (2) Seven detailed sub-studies evaluate the effect of enalapril on a number of intermediate outcomes such as right and LV function and hemodynamics, LV mass and wall stress, hormones, arrhythmias, exercise capacity and quality of life in subsets of patients in the 2 large trials. (3) Finally, a registry of 6,336 patients with congestive heart failure or LV dysfunction is designed to describe the clinical course of an unselected group of patients. The rationale and design of a tiered approach to clinical trials that are large enough to provide reliable information on mortality and morbidity, yet provide relevant information on other endpoints, are described.

Citing Articles

Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.

Natale P, Palmer S, Navaneethan S, Craig J, Strippoli G Cochrane Database Syst Rev. 2024; 4:CD006257.

PMID: 38682786 PMC: 11057222. DOI: 10.1002/14651858.CD006257.pub2.


Pharmacological interventions for heart failure in people with chronic kidney disease.

Lunney M, Ruospo M, Natale P, Quinn R, Ronksley P, Konstantinidis I Cochrane Database Syst Rev. 2020; 2:CD012466.

PMID: 32103487 PMC: 7044419. DOI: 10.1002/14651858.CD012466.pub2.


Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction.

McCallum W, Tighiouart H, Ku E, Salem D, Sarnak M Am J Kidney Dis. 2019; 75(1):21-29.

PMID: 31303349 PMC: 7460181. DOI: 10.1053/j.ajkd.2019.05.010.


Semiparametric Additive Model for Estimating Risk Difference in Multicenter Studies.

Zeng D, Hyun N, Cai J Biostat Epidemiol. 2019; 2(1):84-98.

PMID: 30631827 PMC: 6322696. DOI: 10.1080/24709360.2018.1445430.


[Management of anesthesia in endovascular interventions].

Rossel T, Paul R, Richter T, Ludwig S, Hofmockel T, Heller A Anaesthesist. 2016; 65(12):891-910.

PMID: 27900415 DOI: 10.1007/s00101-016-0241-9.